An independent two-stage DCF analysis by a frontier AI model.
Elevance Health is a quintessential 'toll bridge' business within the US healthcare sector. Operating primarily under the trusted Blue Cross Blue Shield brand in 14 states, it possesses localized scale that is virtually impossible for new entrants to replicate. This scale allows Elevance to negotiate the lowest possible rates with hospitals and physicians, a structural cost advantage that forms the bedrock of its economic moat. While the market frequently overreacts to short-term regulatory noise or minor fluctuations in the Medical Loss Ratio (MLR), the long-term compounding nature of its business remains largely uninterrupted.
The current market price ($291.15) appears to heavily discount recent negative headlines regarding CMS sanctions on certain Medicare Advantage plans. However, this ignores the company's broader diversification and the growing profitability of its Carelon division. Generating over $3 billion in consistent free cash flow, Elevance is fundamentally undervalued, offering a compelling margin of safety for long-term investors willing to look past near-term regulatory volatility.
An 8.0% growth rate reflects Elevance's steady, predictable business model. While premium growth is tied to inflation and population trends, the strategic expansion of Carelon (its higher-margin health services division) is expected to drive high-single-digit free cash flow growth over the medium term, despite near-term Medicare Advantage headwinds.
A 7.5% discount rate is utilized. Elevance's cash flows are highly recession-resistant, as healthcare is a non-discretionary expense. This stability warrants a lower risk premium, though it is slightly elevated by ongoing regulatory and political risks inherent in the US healthcare system.
2.0% represents a conservative terminal rate, aligning with long-term demographic growth and inflation. As a massive, mature player in a saturated domestic market, Elevance's terminal growth is intrinsically linked to the broader US economy.
Intrinsic value per share under varying discount rate and terminal growth rate assumptions.
| WACC ↓ / Terminal → | 1.0% | 1.5% | 2.0% | 2.5% | 3.0% |
|---|---|---|---|---|---|
| 1.0% | $446.60 | $365.40 | $309.18 | $267.96 | $236.44 |
| 1.5% | $502.42 | $401.94 | $334.95 | $287.10 | $251.21 |
| 2.0% | $574.20 | $446.60 | $365.40 | $309.18 | $267.96 |
| 2.5% | $669.90 | $502.42 | $401.94 | $334.95 | $287.10 |
| 3.0% | $803.88 | $574.20 | $446.60 | $365.40 | $309.18 |
■ Undervalued vs current price ■ Overvalued vs current price
The 8.0% growth rate anticipates that while traditional insurance premium growth will remain in the mid-single digits, the continued expansion and integration of Carelon (its health services and pharmacy benefit management arm) will drive higher-margin growth, lifting overall free cash flow.
A 7.5% discount rate was chosen. This reflects the defensive, recession-resistant nature of health insurance cash flows, balanced against the persistent political and regulatory risks associated with government-sponsored healthcare programs.
The model suggests the stock is undervalued because the current market price seems overly punitive regarding recent CMS regulatory news. The core business continues to generate massive, reliable cash flow, and the intrinsic value calculation implies the market is ignoring the long-term earnings power of its expanding Carelon division.
Disclaimer: The numbers presented on this page are for educational and entertainment purposes only. They are the result of a deterministic mathematical model fed with assumptions generated by an Artificial Intelligence (Gemini 3.1). This does not constitute investment advice. Always conduct your own due diligence before investing in the stock market.